Autoimmune versus oligodendrogliopathy: The pathogenesis of multiple sclerosis

Jin Nakahara, Sadakazu Aiso, Norihiro Suzuki

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the central nervous system (CNS); it affect millions of patients worldwide and the number of patients is on the rise. Current treatment options are fairly limited and there is a strong unmet need for disease-targeted therapies for MS. The most widely accepted hypothesis for the pathogenesis of MS is that it is a primary autoimmune disease in which myelin-specific T cells play a central role in the progression of demyelination. According to this hypothesis, a powerful immune suppression or a reconstruction of the immune system to abrogate disease-specific leukocytes early in the development of the disease is expected to halt or even reverse the disease, since remyelination is an exceptionally efficient regenerative process in the CNS. However, recent neuropathological studies have provided evidence of primary oligodendrogliopathy as a cause of demyelination, suggesting that immune reactions may be a mere secondary event in the course of MS. On the other hand, some recent clinical trial results of new immune-suppressive treatments showed a nearly complete blockade of relapses and significant, albeit incomplete, neurological improvement. Therefore, which hypothesis-autoimmunity or oligodendrogliopathy- lights the correct path to a "cure" for MS?

Original languageEnglish
Pages (from-to)325-333
Number of pages9
JournalArchivum Immunologiae et Therapiae Experimentalis
Volume58
Issue number5
DOIs
Publication statusPublished - 2010 Oct 1
Externally publishedYes

Keywords

  • Autoimmune
  • Multiple sclerosis
  • Oligodendrogliopathy
  • Pathogenesis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Autoimmune versus oligodendrogliopathy : The pathogenesis of multiple sclerosis. / Nakahara, Jin; Aiso, Sadakazu; Suzuki, Norihiro.

In: Archivum Immunologiae et Therapiae Experimentalis, Vol. 58, No. 5, 01.10.2010, p. 325-333.

Research output: Contribution to journalReview article

@article{bafdacf324c14908aa8dd99951c2002b,
title = "Autoimmune versus oligodendrogliopathy: The pathogenesis of multiple sclerosis",
abstract = "Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the central nervous system (CNS); it affect millions of patients worldwide and the number of patients is on the rise. Current treatment options are fairly limited and there is a strong unmet need for disease-targeted therapies for MS. The most widely accepted hypothesis for the pathogenesis of MS is that it is a primary autoimmune disease in which myelin-specific T cells play a central role in the progression of demyelination. According to this hypothesis, a powerful immune suppression or a reconstruction of the immune system to abrogate disease-specific leukocytes early in the development of the disease is expected to halt or even reverse the disease, since remyelination is an exceptionally efficient regenerative process in the CNS. However, recent neuropathological studies have provided evidence of primary oligodendrogliopathy as a cause of demyelination, suggesting that immune reactions may be a mere secondary event in the course of MS. On the other hand, some recent clinical trial results of new immune-suppressive treatments showed a nearly complete blockade of relapses and significant, albeit incomplete, neurological improvement. Therefore, which hypothesis-autoimmunity or oligodendrogliopathy- lights the correct path to a {"}cure{"} for MS?",
keywords = "Autoimmune, Multiple sclerosis, Oligodendrogliopathy, Pathogenesis",
author = "Jin Nakahara and Sadakazu Aiso and Norihiro Suzuki",
year = "2010",
month = "10",
day = "1",
doi = "10.1007/s00005-010-0094-x",
language = "English",
volume = "58",
pages = "325--333",
journal = "Archivum Immunologiae et Therapiae Experimentalis",
issn = "0004-069X",
publisher = "Birkhauser Verlag Basel",
number = "5",

}

TY - JOUR

T1 - Autoimmune versus oligodendrogliopathy

T2 - The pathogenesis of multiple sclerosis

AU - Nakahara, Jin

AU - Aiso, Sadakazu

AU - Suzuki, Norihiro

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the central nervous system (CNS); it affect millions of patients worldwide and the number of patients is on the rise. Current treatment options are fairly limited and there is a strong unmet need for disease-targeted therapies for MS. The most widely accepted hypothesis for the pathogenesis of MS is that it is a primary autoimmune disease in which myelin-specific T cells play a central role in the progression of demyelination. According to this hypothesis, a powerful immune suppression or a reconstruction of the immune system to abrogate disease-specific leukocytes early in the development of the disease is expected to halt or even reverse the disease, since remyelination is an exceptionally efficient regenerative process in the CNS. However, recent neuropathological studies have provided evidence of primary oligodendrogliopathy as a cause of demyelination, suggesting that immune reactions may be a mere secondary event in the course of MS. On the other hand, some recent clinical trial results of new immune-suppressive treatments showed a nearly complete blockade of relapses and significant, albeit incomplete, neurological improvement. Therefore, which hypothesis-autoimmunity or oligodendrogliopathy- lights the correct path to a "cure" for MS?

AB - Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the central nervous system (CNS); it affect millions of patients worldwide and the number of patients is on the rise. Current treatment options are fairly limited and there is a strong unmet need for disease-targeted therapies for MS. The most widely accepted hypothesis for the pathogenesis of MS is that it is a primary autoimmune disease in which myelin-specific T cells play a central role in the progression of demyelination. According to this hypothesis, a powerful immune suppression or a reconstruction of the immune system to abrogate disease-specific leukocytes early in the development of the disease is expected to halt or even reverse the disease, since remyelination is an exceptionally efficient regenerative process in the CNS. However, recent neuropathological studies have provided evidence of primary oligodendrogliopathy as a cause of demyelination, suggesting that immune reactions may be a mere secondary event in the course of MS. On the other hand, some recent clinical trial results of new immune-suppressive treatments showed a nearly complete blockade of relapses and significant, albeit incomplete, neurological improvement. Therefore, which hypothesis-autoimmunity or oligodendrogliopathy- lights the correct path to a "cure" for MS?

KW - Autoimmune

KW - Multiple sclerosis

KW - Oligodendrogliopathy

KW - Pathogenesis

UR - http://www.scopus.com/inward/record.url?scp=77956188760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956188760&partnerID=8YFLogxK

U2 - 10.1007/s00005-010-0094-x

DO - 10.1007/s00005-010-0094-x

M3 - Review article

C2 - 20676785

AN - SCOPUS:77956188760

VL - 58

SP - 325

EP - 333

JO - Archivum Immunologiae et Therapiae Experimentalis

JF - Archivum Immunologiae et Therapiae Experimentalis

SN - 0004-069X

IS - 5

ER -